Concord Biotech Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 3 Aug 2026

Company page: Concord Biotech share price, financials & guidance record

Concord Biotech reported a robust Q1 FY27 with significant revenue and profit growth, primarily driven by strong export performance and the API segment. The company achieved substantial margin expansion and made progress on new product launches and regulatory approvals. While the formulation segment saw a decline due to a strategic shift, management expressed confidence in sustaining growth through its product pipeline and new commercial initiatives, targeting long-term revenue and margin goals.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 27.9%, net profit up 41.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	310	244	430	204	247 −20%	278 +14%	326 −24%	261 +28%
Expenses	174	146	239	143	157	176	204	173
EBITDA	137	98	190	61	91 −34%	102 +4%	122 −36%	87 +43%
Margin	44%	40%	44%	30%	37%	37%	38%	33%
Other income	10	15	9	14	13	7	16	13
Interest	0	0	0	0	0	0	0	0
Depreciation	13	13	15	18	18	19	19	18
Profit before tax	133	99	185	57	86 −35%	90 −9%	118 −36%	82 +44%
Tax rate	26%	25%	23%	26%	26%	25%	24%	26%
Net profit	99	74	142	43	63 −36%	68 −8%	90 −37%	61 +42%
EPS	9.43	7.08	13.57	4.07	6.01	6.48	8.60	5.85

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls